KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
KNSALoading price...
Overview
Previous Close43.61
Open46.71
Ask54.50
Bid53.19
Day's Range45.01 - 54.23
52 Week Range24.85 - 54.23
PE Ratio(TTM)59.18
Market Cap4.14B
Volume3M
Avg. Volume691.04k
12 Months Earnings59.01M
12 Months Revenue677.56M
Performance
ABSCAGR
| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 5 Years | 10 Years | |
|---|---|---|---|---|---|---|---|
| No results to display | |||||||
Profit/Loss
| PARTICULARS | TTM | 2025 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Operating Revenue | 677.56M | 677.56M | 529.33M | 423.24M | 270.26M | 220.18M |
| Cost of Revenue | 307.22M | 307.22M | 119.87M | 60.91M | 33.41M | 22.89M |
| Gross Profit | 370.35M | 370.35M | 409.46M | 362.33M | 236.85M | 197.28M |
| Operating Expenses | 293.12M | 293.12M | 404.99M | 407.94M | 262.05M | 187.51M |
| Profit after Tax (Net Income) | 59.01M | 59.01M | 4.79M | -43.19M | 14.08M | 183.36M |
Company Profile
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
HQ Location: London, United Kingdom
Website: https://www.kiniksa.com
CEO & Chairman of the Board: Mr. Sanj K. Patel
Employees: 366
About Company:
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.